A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
Primary Objective:

- To assess the safety, tolerability and plasma pharmacokinetics (PK) of SAR245408 given once daily as a tablet formulation of polymorph E in subjects with solid tumors or lymphoma.
Neoplasm Malignant
DRUG: SAR245408
Dose Limiting Toxicities, Up to Day 28
Number of patients with treatment-emergent adverse events, From first dose of SAR245408 up to 30 days after the last dose|Maximum SAR245408 plasma concentration, Days 1, 2, 8, 15, 29 and 30|Area under the SAR245408 plasma concentration versus time curve, Days 1, 2, 8, 15, 29 and 30
Screening: 1 to 28 days Study treatment period: two 28-day cycles (56 days) End-of-treatment visit: no later than 7 days after the last study drug administration Subjects not eligible for treatment continuation after Cycle 2 will be followed up for safety; a follow-up visit will be performed within 30 Â± 3 days after the last study drug administration Subjects eligible for treatment continuation after Cycle 2 will be offered the opportunity to enroll in the treatment-extension study TED12414.

Total duration of study participation for each patient: 58 to 118 days.